Clinical Studies

WATCHMAN™ LAAC Device: New PREVAIL 5 Year Data from TCT and 5 Year Meta-Analysis results published in JACC

The 5 year combined data from PROTECT-AF and PREVAIL confirmed the safety and efficacy of WATCHMAN™ LAAC Device in stroke prevention. It offered comparable stroke risk reduction as well as statistically significant reductions in disabling and fatal stroke* (-55%), non-procedure related major bleeding (-52%), and mortality (-41% CV death) vs. warfarin after 5 years of follow-up¹.

TCT 2017:
FAME 2 Trial 3-year Outcome and
cost-effectiveness of FFR

Compared with best medical therapy alone, performing PCI in patients with stable CAD and at least one coronary lesion with an abnormal FFR leads to improved clinical outcome, less angina, and improved quality of life at similar cost over three years of follow-up. See the 3-year data from the FAME 2 Trial presented at TCT 2017.

SYNERGY™ BP Stent: outstanding results from the Swedish SCAAR Registry

The SCAAR Registry published data that further solidifies SYNERGY™ BP Stent as one of the best stents in the market today. In the study, SYNERGY™ demonstrated the numerically lowest stent thrombosis rates at 1-year compared to all other newer generation stents combined, despite being used in statistically more complex patients2.

Disclaimer
* Two strokes in PREVAIL are excluded because the baseline MRS score was unavailable
1. Reddy VY, 5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials. DOI: 10.1016/j.jacc.2017.10.021
2. Sarno, G., et al. Cathet. Cardiovasc. Intervent.. doi:10.1002/ccd.27030
 

Top